MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-12-31, INBP had $582K increase in cash & cash equivalents over the period. $593K in free cash flow.

Cash Flow Overview

Change in Cash
$582K
Free Cash flow
$593K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-12-31
2025-09-30
2025-06-30
Net (loss) income
-762 123 808
Amortization of right-of-use assets
253 250 951
Depreciation and amortization
78 77 318
Stock based compensation
42 49 185
Allowance for (charge offs of) uncollectible accounts receivable, net
--19
Loss on disposal of fixed assets
---4
Change in deferred tax assets
-119 68 1,264
Impairment charge on equipment
0 -28
Other, net
4 3 -10
Accounts receivable, net
-391 -1,447 781
Inventories
-2,106 1,107 -1,882
Other assets
114 87 92
Operating lease obligations
---945
Security deposits and other assets
0 --
Accounts payable
-656 533 -211
Accrued expenses and other liabilities
-360 188 -1,355
Operating lease obligations
-246 -243 -
Net cash provided by operating activities
617 1,301 2,065
Purchase of property and equipment
24 173 191
Purchase portion of right of use asset - financed
--14
Net cash used in investing activities
-24 -173 -205
Proceeds from exercise of employee stock options
0 -86
Repayments under finance lease obligations
11 11 8
Net cash provided by (used in) financing activities
-11 -11 78
Net increase in cash
582 1,117 1,938
Cash and cash equivalents at beginning of period
4,732 3,615 1,677
Cash and cash equivalents at end of period
5,314 4,732 3,615
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

INTEGRATED BIOPHARMA INC (INBP)

INTEGRATED BIOPHARMA INC (INBP)